Skip to main content

Table 1 Clinical characteristics of the patients who were diagnosed with MRONJ

From: Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw

Variable Number [n = 86] (%)
Underlying bone disease Osteoporosis 76 (88.4%)
Bone metastasis 6 (9.6%)
Multiple myeloma 4 (6.4%)
MRONJ stage at diagnosis Stage 1 11 (12.8%)
Stage 2 60 (69.8%)
Stage 3 15 (17.4%)
MRONJ location Maxilla 25 (29.1%)
Mandible 58 (67.4%)
Both 3 (3.5%)
Potential risk events Spontaneous 33 (38.4%)
Extraction 38 (44.2%)
Implant surgery 9 (10.5%)
Denture use 6 (7.0%)
Medical comorbidities HTN 52
CVD 15
DM 22
Asthma 4
RA 14
Steroid 15
Thyroid 5
Mental 7
ESRD 2
Liver 1
Duration of BPs exposure 1 year 6 (7.0%)
1~ 2 year 14 (16.3%)
2~ 3 year 19 (22.1%)
3~ 4 year 3 (3.5%)
4~ 5 year 12 (13.9%)
> 5 year 32 (37.2%)
Types of BPs Alendronate 44 (51.2%)
Ibandronate 18 (20.9%)
Risedronate 15 (17.4%)
Pamidronate 3 (3.5%)
Zoledronate 6 (7.0%)
Route of administration PO 70(81.4%)
IV 10 (11.6%)
Both 6 (7.0%)
  1. Since every underlying disease was counted in each patients. Medical comorbidities was over than 86